RVTY
BalancerRevvity
$92.64
+3.16%
as of 13 Apr
Power Core
Revvity's moat is its regulatory embeddedness in newborn screening programs, where switching costs are functionally infinite because the cost of failure is dead children.
Direction of Movement
Lateral Stabilization With Conditional Upward Potential
ROC 200
-7.7%
RVTY
Revvity
$92.64
+3.16%
as of 13 Apr
DCF Fair Value: $115.54
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, expertise, and services delivering complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The company operates through two primary segments: life sciences, which supplies reagents, instruments, and software for biopharma and academic research; and diagnostics, offering tools in immunodiagnostics, newborn screening, and reproductive health. Revvity Inc. serves major markets including the US, Europe, and China, supporting sectors such as healthcare, research, and biopharmaceutical development. Its products and services enable advancements in health sciences by providing end-to-end solutions for scientific discovery and clinical applications. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity Inc. plays a significant role in the diagnostics and research industry.